Roivant Sciences (ROIV) reported fiscal Q3 earnings Monday of $0.23 per diluted share, down from $6.03 a year earlier.
Four analysts polled by FactSet expected a loss of $0.31.
Revenue for the quarter ended Dec. 31 was $9 million, compared with $15.6 million a year earlier.
Analysts surveyed by FactSet expected $5 million.